Phase iii adjuvant doses of epirubicin. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Organisms1

Mice, Inbred BALB C

Diseases28

Breast Neoplasms Neoplasm Metastasis Neoplasm Recurrence, Local Neutropenia Lung Neoplasms Adenocarcinoma Nausea Alopecia Stomach Neoplasms Hematologic Diseases Lymphatic Metastasis Leukopenia Vomiting Disease Progression Carcinoma, Non-Small-Cell Lung Neoplasms Stomatitis Biliary Tract Neoplasms Bone Neoplasms Soft Tissue Neoplasms Pancreatic Neoplasms Colorectal Neoplasms Carcinoma, Small Cell Sarcoma Carcinoma Heart Diseases Liver Neoplasms Ovarian Neoplasms

Chemicals and Drugs43

Epirubicin Adjuvants, Immunologic Fluorouracil Antibiotics, Antineoplastic Cyclophosphamide Freund's Adjuvant Paclitaxel Taxoids Cisplatin Deoxycytidine Doxorubicin Antineoplastic Agents Vinblastine Adjuvants, Pharmaceutic Anthracyclines Razoxane Methotrexate Granulocyte Colony-Stimulating Factor Carboplatin Tamoxifen Leucovorin Ifosfamide Antimetabolites, Antineoplastic Antibodies, Monoclonal, Humanized Antineoplastic Agents, Hormonal Etoposide Vincristine Receptor, erbB-2 Antineoplastic Agents, Phytogenic Organoplatinum Compounds Aluminum Hydroxide Antibodies, Monoclonal Placebos Prolyl Hydroxylases Antineoplastic Agents, Alkylating Mitomycin Tumor Markers, Biological Receptors, Estrogen Vindesine Recombinant Proteins Tegafur Prednisone Naphthacenes

Analytical, Diagnostic and Therapeutic Techniques and Equipment39

Clinical Trials, Phase III as Topic Chemotherapy, Adjuvant Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Treatment Outcome Disease-Free Survival Radiotherapy, Adjuvant Survival Analysis Combined Modality Therapy Neoplasm Staging Survival Rate Infusions, Intravenous Neoadjuvant Therapy Clinical Trials, Phase II as Topic Clinical Trials as Topic Administration, Oral Double-Blind Method Follow-Up Studies Prognosis Randomized Controlled Trials as Topic Kaplan-Meier Estimate Prospective Studies Injections, Intravenous Placebos Proportional Hazards Models Mastectomy Retrospective Studies Remission Induction Maximum Tolerated Dose Immunization Mastectomy, Radical Drug Evaluation Drug Therapy, Combination Dose Fractionation Radiotherapy Dosage Area Under Curve Injections, Subcutaneous Feasibility Studies Research Design

Phenomena and Processes7

Time Factors Dose-Response Relationship, Drug Drug Resistance, Neoplasm Maximum Tolerated Dose Myoelectric Complex, Migrating Area Under Curve Premenopause

Disciplines and Occupations1

Research Design

Anthropology, Education, Sociology and Social Phenomena1

Quality of Life

Humanities1

Quality of Life

Information Science1

Health Care17

Clinical Trials, Phase III as Topic Treatment Outcome Disease-Free Survival Survival Analysis Survival Rate Clinical Trials, Phase II as Topic Clinical Trials as Topic Double-Blind Method Follow-Up Studies Randomized Controlled Trials as Topic Kaplan-Meier Estimate Prospective Studies Proportional Hazards Models Retrospective Studies Immunization Area Under Curve Feasibility Studies

Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Humanities Information Science Health Care

Epirubicin Clinical Trials, Phase III as Topic Chemotherapy, Adjuvant Adjuvants, Immunologic Antineoplastic Combined Chemotherapy Protocols Fluorouracil Antibiotics, Antineoplastic Breast Neoplasms Cyclophosphamide Drug Administration Schedule Treatment Outcome Freund's Adjuvant Disease-Free Survival Paclitaxel Taxoids Radiotherapy, Adjuvant Cisplatin Survival Analysis Deoxycytidine Doxorubicin Combined Modality Therapy Neoplasm Staging Antineoplastic Agents Survival Rate Vinblastine Infusions, Intravenous Neoadjuvant Therapy Adjuvants, Pharmaceutic Anthracyclines Razoxane Methotrexate Neoplasm Metastasis Granulocyte Colony-Stimulating Factor Time Factors Clinical Trials, Phase II as Topic Neoplasm Recurrence, Local Carboplatin Neutropenia Tamoxifen Lung Neoplasms Dose-Response Relationship, Drug Leucovorin Adenocarcinoma Clinical Trials as Topic Administration, Oral Double-Blind Method Follow-Up Studies Prognosis Ifosfamide Randomized Controlled Trials as Topic Nausea Antimetabolites, Antineoplastic Kaplan-Meier Estimate Antibodies, Monoclonal, Humanized Alopecia Prospective Studies Stomach Neoplasms Hematologic Diseases Lymphatic Metastasis Antineoplastic Agents, Hormonal Etoposide Vincristine Leukopenia Vomiting Receptor, erbB-2 Antineoplastic Agents, Phytogenic Disease Progression Carcinoma, Non-Small-Cell Lung Injections, Intravenous Quality of Life Organoplatinum Compounds Aluminum Hydroxide Neoplasms Antibodies, Monoclonal Placebos Proportional Hazards Models Stomatitis Prolyl Hydroxylases Mastectomy Antineoplastic Agents, Alkylating Retrospective Studies Drug Resistance, Neoplasm Remission Induction Maximum Tolerated Dose Mitomycin Tumor Markers, Biological Mice, Inbred BALB C Immunization Receptors, Estrogen Vindesine Mastectomy, Radical Drug Evaluation Recombinant Proteins Drug Therapy, Combination Dose Fractionation Tegafur Prednisone Radiotherapy Dosage Myoelectric Complex, Migrating Biliary Tract Neoplasms

No FAQ available that match "phase iii adjuvant doses of epirubicin"